Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 7 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
INSERM maintains a presence in the Biotechnology & Pharmaceuticals technology area. The organization currently has 1 pending office action, which represents the entirety of its active prosecution workload. This 1 pending office action is assigned to 1 distinct examiner, BURKETT, DANIEL JOHN, who is listed as the busiest examiner with 1 pending office action. This arrangement suggests a centralized approach to the organization's current patent filings.
The prosecution activity is confined to 1 distinct art unit. This concentration suggests a specialized focus within the Biotechnology & Pharmaceuticals sector for the pending matter. Since there is only 1 pending office action and 1 distinct examiner, the organization's current patent office interactions are streamlined. This allows for a targeted approach to resolving the pending matter within the 1 distinct art unit assigned to the case. Legal teams can focus their efforts on the specific requirements of 1 distinct art unit, as the data indicates no other active units are currently involved.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (14%) |
| §103 only | 2 (29%) |
| Multi-statute (no §101) | 4 (57%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CODRINGTON, SHANE WRENSFORD | 1 | 83.3% | +20.8% |
| LOUNTOS, GEORGE THEMISTOCLIS | 1 | 57.1% | +60.0% |
| JAUHARI, SACHI | 1 | 60.0% | +80.0% |
| LIPPERT, JOHN WILLIAM | 1 | 58.2% | +40.0% |
| ROGERS, ERIC JASON | 1 | 57.4% | +32.6% |
| SINGH, ANOOP KUMAR | 1 | 43.0% | +67.6% |
| BRAUN, MADELINE E | 1 | 68.0% | +25.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18871953 | METHOD FOR MODELLING AN ANATOMICAL STRUCTURE OF THE HUMAN BODY | CODRINGTON, SHANE WRENSFORD | — |
| 18693250 | METHOD FOR PURIFYING A PROTEIN OF INTEREST AND MEANS FOR ITS IMPLEMENTATION | LOUNTOS, GEORGE THEMISTOCLIS | — |
| 18573737 | PHARMACEUTICAL COMPOSITIONS COMPRISING GLP-1R AGONISTS | JAUHARI, SACHI | — |
| 18018635 | Immune Cells Defective for SOCS1 | ROGERS, ERIC JASON | — |
| 17921727 | Use of a Synthetic AAV Capsid for Gene Therapy of Muscle and Central Nervous System Disorders | SINGH, ANOOP KUMAR | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18573401 | SONOSENSITIVE COMPOSITION | LIPPERT, JOHN WILLIAM | 72d overdue |
| 18871953 | METHOD FOR MODELLING AN ANATOMICAL STRUCTURE OF THE HUMAN BODY | CODRINGTON, SHANE WRENSFORD | — |
| 18693250 | METHOD FOR PURIFYING A PROTEIN OF INTEREST AND MEANS FOR ITS IMPLEMENTATION | LOUNTOS, GEORGE THEMISTOCLIS | — |
| 18573737 | PHARMACEUTICAL COMPOSITIONS COMPRISING GLP-1R AGONISTS | JAUHARI, SACHI | — |
| 18018635 | Immune Cells Defective for SOCS1 | ROGERS, ERIC JASON | — |
| 17921727 | Use of a Synthetic AAV Capsid for Gene Therapy of Muscle and Central Nervous System Disorders | SINGH, ANOOP KUMAR | — |
| 17494218 | PROPHYLACTIC EFFICACY OF SEROTONIN 4 RECEPTOR AGONISTS AGAINST STRESS | BRAUN, MADELINE E | — |
| Art Unit | Apps |
|---|---|
| 2667 | 1 |
| 1656 | 1 |
| 1654 | 1 |
| 1615 | 1 |
| 1638 | 1 |
| 1632 | 1 |
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18871953 | METHOD FOR MODELLING AN ANATOMICAL STRUCTURE OF THE HUMAN BODY | CODRINGTON, SHANE WRENSFORD | 2667 | §101§103§112 | Non-Final OA | — | Pending | Dec 05, 2024 |
| 18693250 | METHOD FOR PURIFYING A PROTEIN OF INTEREST AND MEANS FOR ITS IMPLEMENTATION | LOUNTOS, GEORGE THEMISTOCLIS | 1656 | §102§103§112 | Non-Final OA | — | Pending | Mar 19, 2024 |
| 18573737 | PHARMACEUTICAL COMPOSITIONS COMPRISING GLP-1R AGONISTS | JAUHARI, SACHI | 1654 | §103§112Other | Non-Final OA | — | Pending | Dec 22, 2023 |
| 18573401 | SONOSENSITIVE COMPOSITION | LIPPERT, JOHN WILLIAM | 1615 | §103 | Final Rejection | 72d overdue | Pending | Dec 21, 2023 |
| 18018635 | Immune Cells Defective for SOCS1 | ROGERS, ERIC JASON | 1638 | §103§112 | Non-Final OA | — | Pending | Jan 30, 2023 |
| 17921727 | Use of a Synthetic AAV Capsid for Gene Therapy of Muscle and Central Nervous System Disorders | SINGH, ANOOP KUMAR | 1632 | §103§112 | Final Rejection | — | Pending | Oct 27, 2022 |
| 17494218 | PROPHYLACTIC EFFICACY OF SEROTONIN 4 RECEPTOR AGONISTS AGAINST STRESS | BRAUN, MADELINE E | 1624 | §103 | Non-Final OA | — | Pending | Oct 05, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial